Navigation Links
Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
Date:11/8/2011

aspirin administration was indefinite.

"For patients treated with Genous, our typical prescription of dual antiplatelet therapy (DAPT) is 30 days," said Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam. "In this large, unselected patient population, there was also a segment of patients who were contraindicated to long-term DAPT and thus received less than 30 days of DAPT. For this reason, it was particularly striking there were only two cases of early stent thrombosis and that no thrombosis was observed after one month through the three year follow up, attesting to the excellent safety profile of Genous in a real world setting."

Please visit the following link to hear Prof. de Winter discuss these data: http://youtu.be/qFLGkc2PaXg.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, th
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
9. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
10. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... HUATULCO, Mexico , July 3, 2015 ... targeting the epidemics of hypertension, diabetes and thyroid disorders ... online educational platforms and a major conference dedicated to ... Manage Diabetes Online , Manage Hypertension ... each developed and operated by EXCEMED - ...
(Date:7/2/2015)... -- Pharma Major Lupin Limited anunció ... ZAO "Biocom" en Rusia bajo ciertas condiciones de ... en el mercado farmacéutico de Rusia que registró ... uno de los 10 principales mercados farmacéuticos del ... una década, el mercado farmacéutico ruso registró un ...
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2015 results on Thursday, July 30, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Latin America With Medical Education 2Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
... MEMPHIS, Tenn., Sept. 9 The National,Coalition ... the proposed cuts to,the HIV/AIDS Medi-Cal pilot ... medications for thousands of Californians living with,HIV/AIDS. ... of recent studies,demonstrating that these pharmacy services ...
... Sept. 9 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) ... Company,s lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the ... Palms Resort & Convention Center in Orlando., ... Date/Time: Tuesday, October 7, 2008 from 10:30 a.m. - ...
Cached Medicine Technology:NCPS Outraged at HIV/AIDS Medi-Cal Cuts 2Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
(Date:7/4/2015)... ... 05, 2015 , ... Dating a real millionaire online can be more difficult. ... service and strives to remove the worries from meeting partners. Recently, the site ... of 2015 and readers have responded with excitement. , “There's quite a ...
(Date:7/4/2015)... California (PRWEB) , ... July 04, 2015 , ... ... earned the solar industry’s leading recognition of technical sales expertise from the North ... PV Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established ...
(Date:7/3/2015)... Greenville, SC (PRWEB) , ... ... ... Society has announced the sessions and speaker lineup for its 2015 ... nursing, taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... Lewisville, TX (PRWEB) , ... July 03, 2015 , ... ... said First Choice Emergency Room , the largest network of independent freestanding emergency ... the new facility medical director of our Sienna Plantation facility,” said Executive Medical Director ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... wooden Al Gore, former US vice president and presently a ... the world Saturday next. ,He is behind the ... and rock music featuring various artists planned to take place ... the global warming crisis. , The concerts have ...
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... out of ten Americans suffer some form of alcohol abuse ... study of drinking and dependency. ,Some 12.5 ... to alcohol dependence during their lives, including 3.8 percent who ... 2001-2002 survey. ,In addition, researchers led by Deborah ...
... announced that a team led by Dr. Yang Xiaofeng ... to assess clinical efficacy, safety, and feasibility of ... peripheral vascular disease of the lower extremities. ... for ataxia, cerebral palsy, spinal cord injury and MS ...
... today that the U.S. Food and Drug Administration (FDA) has ... Tamiflu(R) (oseltamivir phosphate) capsules in 30 mg and 45 mg ... the treatment and prevention of influenza types A and B ... a longer shelf life than the liquid suspension formulation (five ...
... will inaugurate a two-day conference on rural drinking water ... ,The conference will focus on ensuring sustainability in drinking ... rural areas of the country by 2012. ... as, progress under Bharat Nirman, issues of sustainability and ...
Cached Medicine News:Health News:Live Earth Will Make the World More Aware of the Crisis Facing the Earth, Hopes Al Gore 2Health News:Live Earth Will Make the World More Aware of the Crisis Facing the Earth, Hopes Al Gore 3Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Tamiflu 30 Mg and 45 Mg Capsules Approved by FDA 2
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... ToRCH Plus Control is a ... monitor the performance of the ... and assays. A weak positive ... you to monitor the performance ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: